Clinical Trials on Asbestos

PubMed, the National Library of Medicine's index of medical journals, labels every article with its publication type. 419 studies in our library are labeled as studies that test a treatment or test in patients, including randomized controlled trials and trial protocols. The labels are NLM's, not ours. Each entry links to the study on PubMed and to its journal's page in our library, where you can read the abstract.

2020s

• Dual-functIon Semi-rigid thoraCoscOpy Versus semi-rigid thoracoscopy for the diagnosis of plEuRal diseases: protocol for a multicentre, open-label, randomised controlled trial in China (DISCOVER-I). M. Deng, X. Liu, W. Chen, et al. Respiratory Research 2026;27(1). PubMed · Publisher · Free full text

• Evaluation of an educational program for nurses on the care coordination of pleural mesothelioma patients: A pilot randomized controlled trial. Y. Nagamatsu, W. Ono, Y. Sakyo, et al. Japan Journal of Nursing Science 2026;23(1):e70043. Randomized trial PubMed · Publisher · Free full text

• Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. A. Scherpereel, P. Baas, A.K. Nowak, et al. Journal of Clinical Oncology 2026;44(9):742-749. Randomized trial PubMed · Publisher · Free full text

• Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study. M.E. Sobeih, M. Helal, M. Yahia, et al. BMC Cancer 2026;26(1). Randomized trial PubMed · Publisher · Free full text

• Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer. V. Gibson, J. Dzialo, T. Messier, et al. Nature Communications 2026;17(1). PubMed · Publisher · Free full text

• Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma. H.J. Jang, M. Patel, D.Y. Wang, et al. Clinical Cancer Research 2025;31(13):2639-2654. PubMed · Publisher · Free full text

• Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial. D.A. Fennell, K. Hill, M. Zhang, et al. Nature Communications 2025;16(1):6688. Randomized trial PubMed · Publisher · Free full text

• Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy. W.L. Chin, A.M. Cook, J. Chee, et al. Cell Reports. Medicine 2025;6(1):101882. PubMed · Publisher · Free full text

• Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer. L. Chen, A.T. Lucas, A.S. Mansfield, et al. Clinical and Translational Science 2025;18(3):e70178. Randomized trial PubMed · Publisher · Free full text

• First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors. A. Minchom, O. Lindén, D.G. Knapen, et al. ESMO Open 2025;10(12):105905. PubMed · Publisher · Free full text

• KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma. T. Kijima, T. Kato, Y. Goto, et al. Cancer Science 2025;116(8):2208-2217. PubMed · Publisher · Free full text

• Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. S. Thunold, E. Hernes, S. Farooqi, et al. European Journal of Nuclear Medicine and Molecular Imaging 2025;52(2):693-707. Randomized trial PubMed · Publisher · Free full text

• Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses. J.E. Reuss, P.K. Lee, R.J. Mehran, et al. Nature Medicine 2025;31(12):4097-4108. PubMed · Publisher · Free full text

• Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors. J. Fang, O. Jiang, W. Li, et al. Drug Design, Development and Therapy 2025;19:10423-10435. PubMed · Publisher · Free full text

• WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome. Z.N. Berneman, M. De Laere, P. Germonpré, et al. Journal of Hematology & Oncology 2025;18(1):9. Letter PubMed · Publisher · Free full text

• A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma. M. Zhang, A. Bzura, E.Y. Baitei, et al. Nature Communications 2024;15(1):7187. PubMed · Publisher · Free full text

• A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. C.C. Lin, E. Garralda, P. Schöffski, et al. Oncoimmunology 2024;13(1):2290787. PubMed · Publisher · Free full text

• A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205. J. Raskin, V. Surmont, A.P.W.M. Maat, et al. The European Respiratory Journal 2024;63(6). Randomized trial PubMed · Publisher · Free full text

• Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis. Z. Chen, F. Tian, Y. Zhang. Frontiers in Public Health 2024;12:1410355. PubMed · Publisher · Free full text

• Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer. F.R. van 't Land, M. Willemsen, K. Bezemer, et al. Journal of Clinical Oncology 2024;42(26):3083-3093. PubMed · Publisher · Free full text

• Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma. C.S. Cleeland, K.N. Keating, B. Cuffel, et al. Scientific Reports 2024;14(1):14839. PubMed · Publisher · Free full text

• Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial. K. Sakura, M. Kuroyama, Y. Shintani, et al. Cancer Immunology, Immunotherapy 2024;73(12):243. PubMed · Publisher · Free full text

• Effect of intraoperative hyperthermic intrathoracic chemotherapy after pleurectomy decortication for treatment of malignant pleural mesothelioma: a comparative study. H.H. Elsayed, H.Y. Sharkawy, M.A. Ahmed, et al. Updates in Surgery 2024;76(8):2893-2901. PubMed · Publisher · Free full text

• Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. E. Lim, D. Waller, K. Lau, et al. The Lancet. Respiratory Medicine 2024;12(6):457-466. Randomized trial PubMed · Publisher · Free full text

• Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study. J. Van den Bossche, M. De Laere, K. Deschepper, et al. PloS One 2024;19(7):e0307204. PubMed · Publisher · Free full text

• Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. P.W. Szlosarek, B.C. Creelan, T. Sarkodie, et al. JAMA Oncology 2024;10(4):475-483. Randomized trial PubMed · Publisher · Free full text

• Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. A.S. Mansfield, J. Vivien Yin, P. Bradbury, et al. Lung Cancer 2024;195:107928. Randomized trial PubMed · Publisher · Free full text

• UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial. V.D. Haakensen, Å.K. Öjlert, S. Thunold, et al. European Journal of Cancer 2024;202:113973. Randomized trial PubMed · Publisher

• A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. H.S. Lee, H.J. Jang, M. Ramineni, et al. Clinical Cancer Research 2023;29(3):548-559. PubMed · Publisher · Free full text

• Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial. M.V. Dietz, K.L.A. Quintelier, J.P. van Kooten, et al. Journal for Immunotherapy of Cancer 2023;11(8). PubMed · Publisher · Free full text

• Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma. N.K. Chintala, J.K. Choe, E. McGee, et al. Frontiers in Immunology 2023;14:1112960. PubMed · Publisher · Free full text

• Diagnoses and treatments for participants with interstitial lung abnormalities detected in the Yorkshire Lung Screening Trial. S. Upperton, P. Beirne, B. Bhartia, et al. BMJ Open Respiratory Research 2023;10(1). PubMed · Publisher · Free full text

• Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy. A.P. Desai, F. Kosari, M. Disselhorst, et al. Journal for Immunotherapy of Cancer 2023;11(6). PubMed · Publisher · Free full text

• Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres. D. Fennell, D. Griffiths, Z. Eminton, et al. BMJ Open 2023;13(11):e073120. PubMed · Publisher · Free full text

• High-dose IV magnesium in mesothelioma patients receiving surgery with hyperthermic intraoperative cisplatin: Pilot studies and design of a phase II randomized clinical trial. S. Gupta, S.L. Wells, A.M. Jose, et al. Journal of Surgical Oncology 2023;128(7):1141-1149. PubMed · Publisher · Free full text

• MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. L.D. Engstrom, R. Aranda, L. Waters, et al. Cancer Discovery 2023;13(11):2412-2431. PubMed · Publisher · Free full text

• ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. S. Ponce, S. Cedrés, C. Ricordel, et al. Journal for Immunotherapy of Cancer 2023;11(9). Randomized trial PubMed · Publisher · Free full text

• Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial. N. de Rouw, R.J. Boosman, J.A. Burgers, et al. Cancer Chemotherapy and Pharmacology 2023;91(1):33-42. Randomized trial PubMed · Publisher · Free full text

• Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM). A.J. Wozniak, B. Schneider, G.P. Kalemkerian, et al. Clinical Lung Cancer 2023;24(6):563-567. PubMed · Publisher · Free full text

• A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial. E. Maille, J. Levallet, F. Dubois, et al. International Journal of Cancer 2022;150(11):1889-1904. PubMed · Publisher · Free full text

• Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. H.L. Kindler, S. Novello, A. Bearz, et al. The Lancet. Oncology 2022;23(4):540-552. Randomized trial PubMed · Publisher · Free full text

• Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial. P. Muti, A. Sacconi, C. Pulito, et al. Journal of Experimental & Clinical Cancer Research 2022;41(1):255. PubMed · Publisher · Free full text

• Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion. D.B. Fitzgerald, C. Sidhu, C. Budgeon, et al. Trials 2022;23(1):530. PubMed · Publisher · Free full text

• Development and validation of a nomogram for predicting the risk of mental health problems of factory workers and miners. Y. Lu, Q. Liu, H. Yan, et al. BMJ Open 2022;12(7):e057102. Randomized trial PubMed · Publisher · Free full text

• Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma. S. Canova, G.L. Ceresoli, F. Grosso, et al. ESMO Open 2022;7(6):100644. PubMed · Publisher · Free full text

• Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO. J.P. van Kooten, M.V. Dietz, N.A.D. Guchelaar, et al. BMJ Open 2022;12(6):e062907. PubMed · Publisher · Free full text

• Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. O.E. Rahma, K. Tyan, A. Giobbie-Hurder, et al. Journal for Immunotherapy of Cancer 2022;10(3). PubMed · Publisher · Free full text

• Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study. T. Sakurada, H. Nokihara, T. Koga, et al. The Oncologist 2022;27(7):e554-e560. PubMed · Publisher · Free full text

• Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial. P.S. Kok, P.M. Forde, B. Hughes, et al. BMJ Open 2022;12(1):e057663. PubMed · Publisher · Free full text

• A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. A.M. Cook, A. McDonnell, M.J. Millward, et al. Expert Review of Anticancer Therapy 2021;21(5):465-474. PubMed · Publisher

• A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. P.S. Adusumilli, M.G. Zauderer, I. Rivière, et al. Cancer Discovery 2021;11(11):2748-2763. PubMed · Publisher · Free full text

• A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. R. Shah, L.V. Klotz, I. Chung, et al. Clinical Lung Cancer 2021;22(2):142-146. PubMed · Publisher

  In plain English

  This article is a study protocol. It describes a planned clinical trial, called NICITA, that was enrolling patients, and it reports no results. The trial was designed as a randomized, open-label phase II trial at twelve sites in Germany. It planned to include 92 patients with epithelioid malignant pleural mesothelioma, stage I to III. All had already had surgery to remove as much tumor as possible (extended pleurectomy and decortication), with or without heated chemotherapy given into the chest during the operation (HITOC). Every patient was to receive up to four cycles of platinum-based chemotherapy with pemetrexed. Patients in one of the two arms (arm B) were also to receive the immunotherapy drug nivolumab together with the chemotherapy, and then nivolumab alone for up to 12 cycles as maintenance. The authors said the trial would contribute data on how well standard chemotherapy combined with nivolumab works within multi-step treatment of early-stage disease. The article does not examine asbestos exposure.

  We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

• A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. F. Passiglia, P. Bironzo, L. Righi, et al. Clinical Lung Cancer 2021;22(1):e63-e66. PubMed · Publisher

• Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study. T. Nakano, K. Kuribayashi, M. Kondo, et al. Asia-Pacific Journal of Clinical Oncology 2021;17(3):264-272. PubMed · Publisher · Free full text

• Circulating microRNA-197-3p as a potential biomarker for asbestos exposure. F. Frontini, I. Bononi, E. Torreggiani, et al. Scientific Reports 2021;11(1):23955. PubMed · Publisher · Free full text

• CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. R.E. Sanborn, O. Hamid, E.G. de Vries, et al. Journal for Immunotherapy of Cancer 2021;9(7). PubMed · Publisher · Free full text

• Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. P.M. Forde, V. Anagnostou, Z. Sun, et al. Nature Medicine 2021;27(11):1910-1920. PubMed · Publisher · Free full text

• Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. T.A. Yap, K. Nakagawa, N. Fujimoto, et al. The Lancet. Respiratory Medicine 2021;9(6):613-621. PubMed · Publisher

• Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. C. Pinto, P.A. Zucali, M. Pagano, et al. The Lancet. Oncology 2021;22(10):1438-1447. Randomized trial PubMed · Publisher

• JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. Y. Miyamoto, T. Kozuki, K. Aoe, et al. Journal for Immunotherapy of Cancer 2021;9(10). PubMed · Publisher · Free full text

• NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. V.D. Haakensen, A.K. Nowak, E.B. Ellingsen, et al. Journal of Translational Medicine 2021;19(1):232. Randomized trial PubMed · Publisher · Free full text

• Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. D.A. Fennell, S. Ewings, C. Ottensmeier, et al. The Lancet. Oncology 2021;22(11):1530-1540. Randomized trial PubMed · Publisher · Free full text

• Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study. A. Bhatt, P. Rousset, D. Baratti, et al. BMJ Open 2021;11(7):e046819. PubMed · Publisher · Free full text

• Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. M.G. Zauderer, E.W. Alley, J. Bendell, et al. Investigational New Drugs 2021;39(4):1081-1088. PubMed · Publisher · Free full text

• Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J.J. Luke, F. Barlesi, K. Chung, et al. Journal for Immunotherapy of Cancer 2021;9(2). PubMed · Publisher · Free full text

• Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases. R. Ramanathan, H. Choudry, H. Jones, et al. Annals of Surgical Oncology 2021;28(8):4637-4646. PubMed · Publisher · Free full text

• Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. J. Behr, A. Prasse, M. Kreuter, et al. The Lancet. Respiratory Medicine 2021;9(5):476-486. Randomized trial PubMed · Publisher

• Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma. K. Watanabe, Y. Okuma, S. Kawai, et al. Thoracic Cancer 2021;12(11):1668-1672. PubMed · Publisher · Free full text

• Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. D.A. Fennell, A. King, S. Mohammed, et al. The Lancet. Respiratory Medicine 2021;9(6):593-600. Randomized trial PubMed · Publisher

• Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial. S.I. Katz, L. Roshkovan, I. Berger, et al. Lung Cancer 2021;154:5-12. PubMed · Publisher

• Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. B.C.J. Cho, L. Donahoe, P.A. Bradbury, et al. The Lancet. Oncology 2021;22(2):190-197. PubMed · Publisher

• Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. C.J. de Gooijer, V. van der Noort, J.A. Stigt, et al. The Lancet. Respiratory Medicine 2021;9(6):585-592. Randomized trial PubMed · Publisher

• Symptom Burden and Unmet Needs in Malignant Pleural Mesothelioma: Exploratory Analyses From the RESPECT-Meso Study. S.N. Hoon, I. Lawrie, C. Qi, et al. Journal of Palliative Care 2021;36(2):113-120. Randomized trial PubMed · Publisher

• Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. D. Cortinovis, F. Grosso, L. Carlucci, et al. Clinical Lung Cancer 2021;22(4):361-370.e3. PubMed · Publisher

• A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. S. Popat, A. Curioni-Fontecedro, U. Dafni, et al. Annals of Oncology 2020;31(12):1734-1745. PubMed · Publisher

• A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. E.M.J. van Brummelen, E. Levchenko, M. Dómine, et al. Investigational New Drugs 2020;38(2):457-467. PubMed · Publisher · Free full text

• A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). K. Parikh, S.J. Mandrekar, K. Allen-Ziegler, et al. The Oncologist 2020;25(6):523-531. PubMed · Publisher · Free full text

• A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma. P.A. Zucali, M. Perrino, F. De Vincenzo, et al. Lung Cancer 2020;142:132-137. PubMed · Publisher

• A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. C.M. Gay, Y. Zhou, J.J. Lee, et al. The Oncologist 2020;25(10):e1457-e1463. PubMed · Publisher · Free full text

• A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma. W.S. Lam, J. Creaney, F.K. Chen, et al. Lung Cancer 2020;140:87-92. PubMed · Publisher

• Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study. T. Ikeda, S. Takemoto, H. Senju, et al. Thoracic Cancer 2020;11(7):1972-1978. PubMed · Publisher · Free full text

• Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. A. Marabelle, M. Fakih, J. Lopez, et al. The Lancet. Oncology 2020;21(10):1353-1365. PubMed · Publisher

• Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. A.K. Nowak, W.J. Lesterhuis, P.S. Kok, et al. The Lancet. Oncology 2020;21(9):1213-1223. PubMed · Publisher

• Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. R. Chen, W.C. Lee, J. Fujimoto, et al. Clinical Cancer Research 2020;26(20):5477-5486. PubMed · Publisher · Free full text

• First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. R. Hassan, G.R. Blumenschein, K.N. Moore, et al. Journal of Clinical Oncology 2020;38(16):1824-1835. PubMed · Publisher · Free full text

• Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma. H. Taghizadeh, S. Zöchbauer-Müller, R.M. Mader, et al. Thoracic Cancer 2020;11(7):1979-1988. PubMed · Publisher · Free full text

• Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). Y. Metaxas, M. Früh, E.I. Eboulet, et al. Annals of Oncology 2020;31(4):495-500. PubMed · Publisher

• Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. E. Lim, L. Darlison, J. Edwards, et al. BMJ Open 2020;10(9):e038892. PubMed · Publisher · Free full text

• Oncolytic herpesvirus therapy for mesothelioma - A phase I/IIa trial of intrapleural administration of HSV1716. S.J. Danson, J. Conner, J.G. Edwards, et al. Lung Cancer 2020;150:145-151. PubMed · Publisher

• Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas. L.H. Boal, J. Glod, M. Spencer, et al. Clinical Cancer Research 2020;26(23):6112-6121. PubMed · Publisher · Free full text

• Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. B. Geoerger, H.J. Kang, M. Yalon-Oren, et al. The Lancet. Oncology 2020;21(1):121-133. PubMed · Publisher

• Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. R. Hassan, C. Alewine, I. Mian, et al. Cancer 2020;126(22):4936-4947. PubMed · Publisher · Free full text

• Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. M. Van Nuland, H. Rosing, B. Thijssen, et al. Clinical Pharmacology in Drug Development 2020;9(8):929-937. PubMed · Publisher

• Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol. S.N. Hoon, K. Fyfe, C.J. Peddle-McIntyre, et al. BMJ Open Respiratory Research 2020;7(1). PubMed · Publisher · Free full text

• Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. A.Z. Dudek, X. Wang, L. Gu, et al. Clinical Lung Cancer 2020;21(6):553-561.e1. Randomized trial PubMed · Publisher · Free full text

• Short-term integrated rehabilitation for people with newly diagnosed thoracic cancer: a multi-centre randomized controlled feasibility trial. J. Bayly, L. Fettes, E. Douglas, et al. Clinical Rehabilitation 2020;34(2):205-219. Randomized trial PubMed · Publisher

• Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. P. Song, X. Zhang, D. Yang, et al. Thoracic Cancer 2020;11(5):1216-1223. PubMed · Publisher · Free full text

2010s

• A Clinical Trial of TumorGlow to Identify Residual Disease During Pleurectomy and Decortication. J.D. Predina, A.D. Newton, C. Corbett, et al. The Annals of Thoracic Surgery 2019;107(1):224-232. PubMed · Publisher · Free full text
• A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. J.P. Sharman, J.J. Wheler, L. Einhorn, et al. Investigational New Drugs 2019;37(4):738-747. PubMed · Publisher · Free full text
• A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. G. Mak, J.C. Soria, S.P. Blagden, et al. British Journal of Cancer 2019;120(10):975-981. PubMed · Publisher · Free full text
• Adequate nephroprotection reduces renal complications after hyperthermic intrathoracic chemotherapy. T. Markowiak, N. Kerner, R. Neu, et al. Journal of Surgical Oncology 2019;120(7):1220-1226. PubMed · Publisher
• Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. N.L. de Boer, J.P. van Kooten, J.W.A. Burger, et al. BMJ Open 2019;9(5):e026779. PubMed · Publisher · Free full text
• Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. R. Hassan, E. Alley, H. Kindler, et al. Clinical Cancer Research 2019;25(19):5787-5798. PubMed · Publisher · Free full text
• Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma. F. Li, M. Ahmad, F. Qayyum, et al. European Radiology 2019;29(6):2981-2988. Randomized trial PubMed · Publisher
• Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status. P. Baverel, L. Roskos, M. Tatipalli, et al. Clinical and Translational Science 2019;12(5):450-458. Randomized trial PubMed · Publisher · Free full text
• In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma. E. Lopci, P. Novellis, A. Testori, et al. Nuclear Medicine Communications 2019;40(11):1179-1186. PubMed · Publisher
• Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases. L.S. Kyang, N.A. Alzahrani, S.J. Valle, et al. Journal of Surgical Oncology 2019;120(4):794-802. PubMed · Publisher
• MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial. C. Matthews, C. Freeman, L.D. Sharples, et al. BMJ Open Respiratory Research 2019;6(1):e000368. PubMed · Publisher · Free full text
• MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. E. Maille, S. Brosseau, V. Hanoux, et al. British Journal of Cancer 2019;120(4):387-397. Randomized trial PubMed · Publisher · Free full text
• Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. G.V. Scagliotti, R. Gaafar, A.K. Nowak, et al. The Lancet. Respiratory Medicine 2019;7(7):569-580. Randomized trial PubMed · Publisher
• Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. A. Scherpereel, J. Mazieres, L. Greillier, et al. The Lancet. Oncology 2019;20(2):239-253. Randomized trial PubMed · Publisher
• Optimization of Second Window Indocyanine Green for Intraoperative Near-Infrared Imaging of Thoracic Malignancy. A.D. Newton, J.D. Predina, C.J. Corbett, et al. Journal of the American College of Surgeons 2019;228(2):188-197. PubMed · Publisher · Free full text
• Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. O. Riesterer, I.F. Ciernik, R.A. Stahel, et al. Radiotherapy and Oncology 2019;138:121-125. Randomized trial PubMed · Publisher
• Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. M. Takeda, Y. Ohe, H. Horinouchi, et al. Lung Cancer 2019;137:64-70. PubMed · Publisher
• Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial. M.W. Marcus, S.W. Duffy, A. Devaraj, et al. Thorax 2019;74(8):761-767. Randomized trial PubMed · Publisher
• Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma. R. White, E. Pulford, D.J. Elliot, et al. Journal of Proteomics 2019;192:374-382. PubMed · Publisher
• Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. S. Brosseau, C. Danel, A. Scherpereel, et al. Clinical Lung Cancer 2019;20(5):e564-e575. Randomized trial PubMed · Publisher
• The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease. F. Khan, I. Stewart, L. Howard, et al. BMJ Open Respiratory Research 2019;6(1):e000439. PubMed · Publisher · Free full text
• Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings. N. Ueno, S. Banno, Y. Endo, et al. Japanese Journal of Clinical Oncology 2019;49(7):676-686. PubMed · Publisher
• Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. G.L. Ceresoli, J.G. Aerts, R. Dziadziuszko, et al. The Lancet. Oncology 2019;20(12):1702-1709. PubMed · Publisher
• 18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma. D.O. Hall, C.E. Hooper, J. Searle, et al. Nuclear Medicine Communications 2018;39(2):161-170. PubMed · Publisher
• A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma. B.M. Burt, W.G. Richards, H.S. Lee, et al. Journal of Thoracic Oncology 2018;13(9):1400-1409. PubMed · Publisher
• A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol. N. Fujimoto, K. Aoe, T. Kozuki, et al. Clinical Lung Cancer 2018;19(5):e705-e707. PubMed · Publisher
• A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy. R.W. Davis, E. Papasavvas, A. Klampatsa, et al. Lasers in Surgery and Medicine 2018;50(5):440-450. Randomized trial PubMed · Publisher · Free full text
• Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. S. Muruganandan, M. Azzopardi, D.B. Fitzgerald, et al. The Lancet. Respiratory Medicine 2018;6(9):671-680. Randomized trial PubMed · Publisher
• CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. D.A. Fennell, E. Kirkpatrick, K. Cozens, et al. Trials 2018;19(1):233. PubMed · Publisher · Free full text
• Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread: A French nationwide study over 14 years. A. Scalabre, P. Philippe-Chomette, G. Passot, et al. Pediatric Blood & Cancer 2018;65(4). PubMed · Publisher
• Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. A.S. Mansfield, T. Peikert, N.J. Vogelzang, et al. Mayo Clinic Proceedings 2018;93(8):1026-1033. Randomized trial PubMed · Publisher · Free full text
• Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial. S.A. Stewart, A.O. Clive, N.A. Maskell, et al. PloS One 2018;13(2):e0190257. Randomized trial PubMed · Publisher · Free full text
• Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. W.T. Vigneswaran, D.Y. Kircheva, A.E. Rodrigues, et al. World Journal of Surgery 2018;42(4):1036-1045. PubMed · Publisher
• Methylation-derived Neutrophil-to-Lymphocyte Ratio and Lung Cancer Risk in Heavy Smokers. L. Grieshober, S. Graw, M.J. Barnett, et al. Cancer Prevention Research 2018;11(11):727-734. Randomized trial PubMed · Publisher · Free full text
• NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. V. Gregorc, R.M. Gaafar, A. Favaretto, et al. The Lancet. Oncology 2018;19(6):799-811. Randomized trial PubMed · Publisher
• Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. H.J. Gray, K. Bell-McGuinn, G.F. Fleming, et al. Gynecologic Oncology 2018;148(3):507-514. PubMed · Publisher
• Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. R. Bahleda, M.C. Le Deley, A. Bernard, et al. Investigational New Drugs 2018;36(4):619-628. PubMed · Publisher
• Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. J. Quispel-Janssen, V. van der Noort, J.F. de Vries, et al. Journal of Thoracic Oncology 2018;13(10):1569-1576. PubMed · Publisher
• Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma. R.R. Gill, B.Y. Yeap, R. Bueno, et al. Journal of the National Cancer Institute 2018;110(3):258-264. Randomized trial PubMed · Publisher · Free full text
• Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. L. Calabrò, A. Morra, D. Giannarelli, et al. The Lancet. Respiratory Medicine 2018;6(6):451-460. PubMed · Publisher
• Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial. D. de Fonseka, A. Morley, L. Stadon, et al. Trials 2018;19(1):467. Randomized trial PubMed · Publisher · Free full text
• A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. S.A. Laurie, D. Hao, N.B. Leighl, et al. Lung Cancer 2017;104:65-69. PubMed · Publisher
• A randomised assessment of the use of a quality of life questionnaire with or without intervention in patients attending a thoracic cancer clinic. K. Nimako, B. Ayite, K. Priest, et al. European Journal of Cancer Care 2017;26(4). Randomized trial PubMed · Publisher
• A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. M.G. Zauderer, A.S. Tsao, T. Dao, et al. Clinical Cancer Research 2017;23(24):7483-7489. Randomized trial PubMed · Publisher · Free full text
• Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. E.W. Alley, J. Lopez, A. Santoro, et al. The Lancet. Oncology 2017;18(5):623-630. PubMed · Publisher
• Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. K. Goričar, V. Kovač, V. Dolžan. Scientific Reports 2017;7:46537. PubMed · Publisher · Free full text
• Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial. M. Zhan, H. Zheng, T. Xu, et al. Lung Cancer 2017;110:1-6. Randomized trial PubMed · Publisher
• Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. J. Behr, P. Neuser, A. Prasse, et al. BMC Pulmonary Medicine 2017;17(1):122. Randomized trial PubMed · Publisher · Free full text
• First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. E. Angevin, N. Isambert, V. Trillet-Lenoir, et al. British Journal of Cancer 2017;116(9):1126-1134. PubMed · Publisher · Free full text
• LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. G.V. Scagliotti, R. Gaafar, A.K. Nowak, et al. Clinical Lung Cancer 2017;18(5):589-593. Randomized trial PubMed · Publisher
• Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients. F. Barlesi, D.C. Imbs, P. Tomasini, et al. Oncotarget 2017;8(29):47161-47166. PubMed · Publisher · Free full text
• Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. E. Beddowes, J. Spicer, P.Y. Chan, et al. Journal of Clinical Oncology 2017;35(16):1778-1785. PubMed · Publisher · Free full text
• Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. S. Aspeslagh, K. Shailubhai, R. Bahleda, et al. Cancer Chemotherapy and Pharmacology 2017;79(6):1257-1265. PubMed · Publisher
• Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). A.S. Tsao, J. Moon, I.I. Wistuba, et al. Journal of Thoracic Oncology 2017;12(8):1299-1308. PubMed · Publisher · Free full text
• Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy. T. Takuwa, M. Hashimoto, S. Matsumoto, et al. International Journal of Clinical Oncology 2017;22(5):857-864. PubMed · Publisher
• Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. N. van Zandwijk, N. Pavlakis, S.C. Kao, et al. The Lancet. Oncology 2017;18(10):1386-1396. PubMed · Publisher
• The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. L.M. Dowman, C.F. McDonald, C.J. Hill, et al. Thorax 2017;72(7):610-619. Randomized trial PubMed · Publisher
• The feasibility of contrast enhanced ultrasonography (CEUS) in the diagnosis of non-cardiac thoracic disorders of dogs and cats. N. Linta, M. Baron Toaldo, G. Bettini, et al. BMC Veterinary Research 2017;13(1):141. PubMed · Publisher · Free full text
• Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. M. Maio, A. Scherpereel, L. Calabrò, et al. The Lancet. Oncology 2017;18(9):1261-1273. Randomized trial PubMed · Publisher
• Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. X. Wang, X. Wang, L. Hodgson, et al. The Oncologist 2017;22(2):189-198. PubMed · Publisher · Free full text
• A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. T. Shimizu, K. Fukuoka, M. Takeda, et al. Cancer Chemotherapy and Pharmacology 2016;77(5):997-1003. PubMed · Publisher · Free full text
• A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. J.M. Baumgartner, T.G. Kwong, G.L. Ma, et al. Annals of Surgical Oncology 2016;23(5):1609-17. PubMed · Publisher · Free full text
• A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. D. Jamieson, M.J. Griffin, J. Sludden, et al. European Journal of Cancer 2016;68:1-10. PubMed · Publisher
• A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. J.C. Soria, H.K. Gan, S.P. Blagden, et al. Annals of Oncology 2016;27(12):2268-2274. PubMed · Publisher
• A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. X. Elharrar, D. Barbolosi, J. Ciccolini, et al. BMC Cancer 2016;16:278. PubMed · Publisher · Free full text
• A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207. P. Wheatley-Price, Q. Chu, M. Bonomi, et al. Journal of Thoracic Oncology 2016;11(11):2018-2021. PubMed · Publisher
• A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma. A. Minchom, R. Punwani, J. Filshie, et al. European Journal of Cancer 2016;61:102-10. Randomized trial PubMed · Publisher
• A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes. W.A. Buikhuisen, M. Scharpfenecker, A.W. Griffioen, et al. Journal of Thoracic Oncology 2016;11(5):758-768. Randomized trial PubMed · Publisher
• Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. M. de Perrot, R. Feld, N.B. Leighl, et al. The Journal of Thoracic and Cardiovascular Surgery 2016;151(2):468-73. PubMed · Publisher
• Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. G. Zalcman, J. Mazieres, J. Margery, et al. Lancet 2016;387(10026):1405-1414. Randomized trial PubMed · Publisher
• CT Scan-Guided Abrams' Needle Pleural Biopsy versus Ultrasound-Assisted Cutting Needle Pleural Biopsy for Diagnosis in Patients with Pleural Effusion: A Randomized, Controlled Trial. M. Metintas, H. Yildirim, T. Kaya, et al. Respiration; International Review of Thoracic Diseases 2016;91(2):156-63. Randomized trial PubMed · Publisher
• Diagnostic Performance of Ultra-Low-Dose Computed Tomography for Detecting Asbestos-Related Pleuropulmonary Diseases: Prospective Study in a Screening Setting. M. Schaal, F. Severac, A. Labani, et al. PloS One 2016;11(12):e0168979. PubMed · Publisher · Free full text
• Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis. S. Miyoshi, S. Sasada, T. Izumo, et al. PloS One 2016;11(11):e0167186. PubMed · Publisher · Free full text
• Elemental analysis of histological specimens: a method to unmask nano asbestos fibers. M. Scimeca, A. Pietroiusti, F. Milano, et al. European Journal of Histochemistry 2016;60(1):2573. Randomized trial PubMed · Publisher · Free full text
• Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model. J.M. Porcel, A. Esquerda, M. Martínez-Alonso, et al. Medicine 2016;95(10):e3044. Randomized trial PubMed · Publisher · Free full text
• Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery. R.A. Marmor, K.J. Kelly, A.M. Lowy, et al. Annals of Surgical Oncology 2016;23(5):1461-7. PubMed · Publisher
• Pain in Malignant Pleural Mesothelioma: A Prospective Characterization Study. N. MacLeod, C. Kelly, J. Stobo, et al. Pain Medicine 2016;17(11):2119-2126. PubMed · Publisher
• Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. S.O. Dolly, A.J. Wagner, J.C. Bendell, et al. Clinical Cancer Research 2016;22(12):2874-84. PubMed · Publisher · Free full text
• Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy. D.H. Sterman, E. Alley, J.P. Stevenson, et al. Clinical Cancer Research 2016;22(15):3791-800. PubMed · Publisher · Free full text
• Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. A.O. Clive, H. Taylor, L. Dobson, et al. The Lancet. Oncology 2016;17(8):1094-1104. Randomized trial PubMed · Publisher · Free full text
• Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. N. Bayman, D. Ardron, L. Ashcroft, et al. BMJ Open 2016;6(1):e010589. Randomized trial PubMed · Publisher · Free full text
• Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters. M. Azzopardi, R. Thomas, S. Muruganandan, et al. BMJ Open 2016;6(7):e011480. Randomized trial PubMed · Publisher · Free full text
• Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial). S. Hasegawa, M. Okada, F. Tanaka, et al. International Journal of Clinical Oncology 2016;21(3):523-30. PubMed · Publisher · Free full text
• A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. J.E. Gray, J.R. Infante, L.H. Brail, et al. Investigational New Drugs 2015;33(6):1187-96. PubMed · Publisher
• A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. A.K. Nowak, A.M. Cook, A.M. McDonnell, et al. Annals of Oncology 2015;26(12):2483-90. PubMed · Publisher
• Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases. A. Hayes-Jordan, H. Green, H. Lin, et al. Annals of Surgical Oncology 2015;22(5):1726-32. PubMed · Publisher
• Effect of N-acetylcysteine supplementation on oxidative stress status and alveolar inflammation in people exposed to asbestos: a double-blind, randomized clinical trial. H. Alfonso, P. Franklin, S. Ching, et al. Respirology 2015;20(7):1102-7. Randomized trial PubMed · Publisher
• Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. L. Calabrò, A. Morra, E. Fonsatti, et al. The Lancet. Respiratory Medicine 2015;3(4):301-9. PubMed · Publisher
• Expression status of candidate genes in mesothelioma tissues and cell lines. O. Melaiu, E. Melissari, L. Mutti, et al. Mutation Research 2015;771:6-12. PubMed · Publisher
• First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. M.J. Ratain, D. Geary, S.D. Undevia, et al. Investigational New Drugs 2015;33(4):901-10. PubMed · Publisher
• Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: Toxicity and outcomes at an Australian institution. A. Bece, M.M. Tin, D. Martin, et al. Journal of Medical Imaging and Radiation Oncology 2015;59(3):355-62. PubMed · Publisher
• Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial. N. MacLeod, A. Chalmers, N. O'Rourke, et al. Journal of Thoracic Oncology 2015;10(6):944-50. PubMed · Publisher
• Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. R.A. Stahel, O. Riesterer, A. Xyrafas, et al. The Lancet. Oncology 2015;16(16):1651-8. Randomized trial PubMed · Publisher
• Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Y. Fujisaka, T. Kurata, K. Tanaka, et al. Investigational New Drugs 2015;33(2):380-8. PubMed · Publisher · Free full text
• Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases. A.O. Clive, P. Wilson, H. Taylor, et al. BMJ Open 2015;5(1):e006673. Randomized trial PubMed · Publisher · Free full text
• Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. L. Lindenberg, A. Thomas, S. Adler, et al. Oncotarget 2015;6(6):4496-504. PubMed · Publisher · Free full text
• SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). S.H. Ou, J. Moon, L.L. Garland, et al. Journal of Thoracic Oncology 2015;10(2):387-91. PubMed · Publisher · Free full text
• The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma. G. Ak, S. Metintas, M. Akarsu, et al. BMC Cancer 2015;15:510. PubMed · Publisher · Free full text
• Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. L.M. Krug, H.L. Kindler, H. Calvert, et al. The Lancet. Oncology 2015;16(4):447-56. Randomized trial PubMed · Publisher
• A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma. B.C. Cho, R. Feld, N. Leighl, et al. Journal of Thoracic Oncology 2014;9(3):397-402. PubMed · Publisher
• A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial. S. Gunatilake, F.J. Brims, C. Fogg, et al. Trials 2014;15:367. Randomized trial PubMed · Publisher · Free full text
• A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. O. Arrieta, D. López-Macías, V.O. Mendoza-García, et al. Cancer Chemotherapy and Pharmacology 2014;73(5):975-82. PubMed · Publisher
• Asbestos-induced disruption of calcium homeostasis induces endoplasmic reticulum stress in macrophages. A.J. Ryan, J.L. Larson-Casey, C. He, et al. The Journal of Biological Chemistry 2014;289(48):33391-403. PubMed · Publisher · Free full text
• Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution. J. Raphael, G. Le Teuff, A. Hollebecque, et al. Lung Cancer 2014;85(2):251-7. PubMed · Publisher
• Exercise training for asbestos-related and other dust-related respiratory diseases: a randomised controlled trial. M.T. Dale, Z.J. McKeough, P.A. Munoz, et al. BMC Pulmonary Medicine 2014;14:180. Randomized trial PubMed · Publisher · Free full text
• Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions. O. Lauk, M.A. Hoda, M. de Perrot, et al. The Annals of Thoracic Surgery 2014;98(5):1748-54. Randomized trial PubMed · Publisher
• High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin. O. Arrieta, L.A. Medina, E. Estrada-Lobato, et al. Cancer Chemotherapy and Pharmacology 2014;74(1):211-5. PubMed · Publisher
• Impact of a nursing education program about caring for patients in Japan with malignant pleural mesothelioma on nurses' knowledge, difficulties and attitude: a randomized control trial. Y. Nagamatsu, Y. Natori, H. Yanai, et al. Nurse Education Today 2014;34(7):1087-93. Randomized trial PubMed · Publisher
• Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. G.L. Beatty, A.R. Haas, M.V. Maus, et al. Cancer Immunology Research 2014;2(2):112-20. PubMed · Publisher · Free full text
• Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. R. Hassan, E. Sharon, A. Thomas, et al. Cancer 2014;120(21):3311-9. PubMed · Publisher · Free full text
• Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. A.S. Tsao, N. Harun, J.J. Lee, et al. Clinical Lung Cancer 2014;15(3):197-201. PubMed · Publisher · Free full text
• Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. R. Hassan, H.L. Kindler, T. Jahan, et al. Clinical Cancer Research 2014;20(23):5927-36. PubMed · Publisher · Free full text
• Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation. B. Hasan, L. Greillier, A. Pallis, et al. European Journal of Cancer 2014;50(16):2771-82. PubMed · Publisher
• Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. L.M. Krug, A.J. Wozniak, H.L. Kindler, et al. Lung Cancer 2014;85(3):429-34. Randomized trial PubMed · Publisher
• Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. J. Wong, A.L. Koch, J.L. Deneve, et al. Annals of Surgical Oncology 2014;21(5):1480-6. PubMed · Publisher
• Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. H. Mutlu, S. Gündüz, H. Karaca, et al. Medical Oncology 2014;31(8):74. PubMed · Publisher
• Should we continue to offer extrapleural pneumonectomy to selected mesothelioma patients? A single center experience comparing surgical and non-surgical management. M. Baud, A. Bobbio, F. Lococo, et al. Japanese Journal of Clinical Oncology 2014;44(11):1127-9. PubMed · Publisher
• The clinicopathological characteristics with long-term outcomes in malignant mesothelioma. M. Dogan, G. Utkan, C. Hocazade, et al. Medical Oncology 2014;31(10):232. PubMed · Publisher
• Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC. M. Robella, M. Vaira, A. Mellano, et al. Minerva Chirurgica 2014;69(1):9-15. PubMed
• A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma. M. Shimokawa, S. Hasegawa, K. Fukuoka, et al. Japanese Journal of Clinical Oncology 2013;43(5):575-8. PubMed · Publisher
• A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. A.K. Nowak, C. Brown, M.J. Millward, et al. Lung Cancer 2013;81(3):422-427. PubMed · Publisher
• A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. C.E. Hooper, A.J. Morley, P. Virgo, et al. The European Respiratory Journal 2013;41(1):18-24. PubMed · Publisher
• A tailored, supportive care intervention using systematic assessment designed for people with inoperable lung cancer: a randomised controlled trial. P. Schofield, A. Ugalde, K. Gough, et al. Psycho-oncology 2013;22(11):2445-53. Randomized trial PubMed · Publisher
• An open-label phase I pilot study of continuous intrapleural infusion of escalated doses of methotrexate in malignant pleural mesothelioma. M.M. Ellithy, N.S. El Baghdady, L.M. El Wakeel, et al. American Journal of Clinical Oncology 2013;36(5):514-8. PubMed · Publisher
• Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens. E.E. Habib, E.S. Fahmy. Clinical & Translational Oncology 2013;15(11):965-8. Randomized trial PubMed · Publisher
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution. M.C. Teo, G.H. Tan, C.K. Tham, et al. Annals of Surgical Oncology 2013;20(9):2968-74. PubMed · Publisher
• Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. M. Ried, T. Potzger, N. Braune, et al. European Journal of Cardio-thoracic Surgery 2013;43(4):801-7. PubMed · Publisher
• Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. S.C. Kao, J. Vardy, R. Harvie, et al. Supportive Care in Cancer 2013;21(3):697-705. PubMed · Publisher
• Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. R. Hassan, A.C. Miller, E. Sharon, et al. Science Translational Medicine 2013;5(208):208ra147. PubMed · Publisher · Free full text
• No dose-dependent increase in fracture risk after long-term exposure to high doses of retinol or beta-carotene. G.L. Ambrosini, A.P. Bremner, A. Reid, et al. Osteoporosis International 2013;24(4):1285-93. Randomized trial PubMed · Publisher
• Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas. S. Kummar, M.E. Gutierrez, L.W. Anderson, et al. Cancer Chemotherapy and Pharmacology 2013;72(4):917-23. PubMed · Publisher · Free full text
• Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. S. Papa, S. Popat, R. Shah, et al. Journal of Thoracic Oncology 2013;8(6):783-7. PubMed · Publisher
• Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). M.E. O'Brien, R.M. Gaafar, S. Popat, et al. European Journal of Cancer 2013;49(13):2815-22. PubMed · Publisher
• Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. G.L. Ceresoli, P.A. Zucali, M. Mencoboni, et al. British Journal of Cancer 2013;109(3):552-8. PubMed · Publisher · Free full text
• Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. R. Federico, F. Adolfo, M. Giuseppe, et al. BMC Cancer 2013;13:22. PubMed · Publisher · Free full text
• Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk?. N. Tsilimparis, C. Bockelmann, W. Raue, et al. Annals of Surgical Oncology 2013;20(1):226-32. PubMed · Publisher
• Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. N. Blais, D.R. Camidge, D.J. Jonker, et al. Investigational New Drugs 2013;31(6):1487-98. PubMed · Publisher · Free full text
• Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. D.R. Camidge, N. Blais, D.J. Jonker, et al. Cancer Chemotherapy and Pharmacology 2013;71(2):307-19. PubMed · Publisher
• T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. M.V. Maus, A.R. Haas, G.L. Beatty, et al. Cancer Immunology Research 2013;1(1):26-31. Case report PubMed · Publisher · Free full text
• Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. W.A. Buikhuisen, J.A. Burgers, A.D. Vincent, et al. The Lancet. Oncology 2013;14(6):543-51. Randomized trial PubMed · Publisher
• The impact of individual quality of life assessment on psychosocial attention in patients with chest malignancies: a randomized study. M. Nicklasson, M.L. Elfström, J. Olofson, et al. Supportive Care in Cancer 2013;21(1):87-95. Randomized trial PubMed · Publisher
• Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. L. Calabrò, A. Morra, E. Fonsatti, et al. The Lancet. Oncology 2013;14(11):1104-1111. PubMed · Publisher
• Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. A.M. Gonzalez-Angulo, F. Meric-Bernstam, S. Chawla, et al. Clinical Cancer Research 2013;19(19):5474-84. PubMed · Publisher · Free full text
• A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. Z.G. Zimling, J.B. Sørensen, T.A. Gerds, et al. Cancer Chemotherapy and Pharmacology 2012;70(5):743-54. PubMed · Publisher
• A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. D.T. Le, D.G. Brockstedt, R. Nir-Paz, et al. Clinical Cancer Research 2012;18(3):858-68. PubMed · Publisher · Free full text
• A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. J.E. Dowell, F.R. Dunphy, R.N. Taub, et al. Lung Cancer 2012;77(3):567-71. PubMed · Publisher
• A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. A.K. Nowak, M.J. Millward, J. Creaney, et al. Journal of Thoracic Oncology 2012;7(9):1449-56. PubMed · Publisher
• A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. V. Kovac, M. Zwitter, M. Rajer, et al. Anti-cancer Drugs 2012;23(2):230-8. PubMed · Publisher
• Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment. S. Lorentini, M. Amichetti, L. Spiazzi, et al. Strahlentherapie und Onkologie 2012;188(3):216-25. PubMed · Publisher
• An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls. S. Dragonieri, M.P. van der Schee, T. Massaro, et al. Lung Cancer 2012;75(3):326-31. PubMed · Publisher
• Anesthetic management and renal function in pediatric patients undergoing cytoreductive surgery with continuous hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin. P. Owusu-Agyemang, R. Arunkumar, H. Green, et al. Annals of Surgical Oncology 2012;19(8):2652-6. PubMed · Publisher
• Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. N.P. Campbell, R. Kunnavakkam, N. Leighl, et al. Lung Cancer 2012;78(1):76-80. PubMed · Publisher · Free full text
• CT scan screening for lung cancer: risk factors for nodules and malignancy in a high-risk urban cohort. A.K. Greenberg, F. Lu, J.D. Goldberg, et al. PloS One 2012;7(7):e39403. PubMed · Publisher · Free full text
• First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Ó. Arrieta, L.A. Medina, E. Estrada-Lobato, et al. British Journal of Cancer 2012;106(6):1027-32. PubMed · Publisher · Free full text
• Fluorescence thoracoscopy in the detection of pleural malignancy. O. Pikin, E. Filonenko, D. Mironenko, et al. European Journal of Cardio-thoracic Surgery 2012;41(3):649-52. PubMed · Publisher
• Hemithoracic intensity-modulated radiotherapy using helical tomotherapy for patients after extrapleural pneumonectomy for malignant pleural mesothelioma. T. Ebara, H. Kawamura, T. Kaminuma, et al. Journal of Radiation Research 2012;53(2):288-94. Case report PubMed · Publisher
• Initial experience with the use of biological implants for soft tissue and chest wall reconstruction in thoracic surgery. A. Barua, J.A. Catton, L. Socci, et al. The Annals of Thoracic Surgery 2012;94(5):1701-5. PubMed · Publisher
• Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption. K. Hollevoet, M.M. Speeckaert, A.S. Decavele, et al. Clinical Lung Cancer 2012;13(6):470-4. PubMed · Publisher
• Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. B. Saraiya, R. Chugh, V. Karantza, et al. Investigational New Drugs 2012;30(1):258-65. PubMed · Publisher · Free full text
• Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. D.A. Fennell, C. McDowell, S. Busacca, et al. Journal of Thoracic Oncology 2012;7(9):1466-70. PubMed · Publisher
• Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. A.Z. Dudek, H. Pang, R.A. Kratzke, et al. Journal of Thoracic Oncology 2012;7(4):755-9. PubMed · Publisher · Free full text
• Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). U. Petrausch, P.C. Schuberth, C. Hagedorn, et al. BMC Cancer 2012;12:615. PubMed · Publisher · Free full text
• Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study. K. Kuribayashi, S. Voss, S. Nishiuma, et al. Lung Cancer 2012;75(3):353-9. PubMed · Publisher
• Specific expression of human intelectin-1 in malignant pleural mesothelioma and gastrointestinal goblet cells. K. Washimi, T. Yokose, M. Yamashita, et al. PloS One 2012;7(7):e39889. PubMed · Publisher · Free full text
• Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: early experience and phase 1 results. A. Hayes-Jordan, H. Green, J. Ludwig, et al. Pediatric Blood & Cancer 2012;59(2):395-7. PubMed · Publisher
• Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). T. Jahan, L. Gu, R. Kratzke, et al. Lung Cancer 2012;76(3):393-6. PubMed · Publisher · Free full text
• A randomized controlled trial of the efficacy of cosmetic talc compared with iodopovidone for chemical pleurodesis. R. Agarwal, A.S. Paul, A.N. Aggarwal, et al. Respirology 2011;16(7):1064-9. Randomized trial PubMed · Publisher
• Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. S.A. Laurie, A. Gupta, Q. Chu, et al. Journal of Thoracic Oncology 2011;6(11):1950-4. PubMed · Publisher
• Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. T. Treasure, L. Lang-Lazdunski, D. Waller, et al. The Lancet. Oncology 2011;12(8):763-72. Randomized trial PubMed · Publisher · Free full text
• Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. T. Takahashi, Y. Nakamura, A. Tsuya, et al. Cancer Chemotherapy and Pharmacology 2011;68(3):653-9. Randomized trial PubMed · Publisher · Free full text
• Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. L.L. Garland, K. Chansky, A.J. Wozniak, et al. Journal of Thoracic Oncology 2011;6(11):1938-45. PubMed · Publisher · Free full text
• Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study. I. Tourkantonis, N. Makrilia, M. Ralli, et al. American Journal of Clinical Oncology 2011;34(1):38-42. PubMed · Publisher
• Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. K. Kadota, K. Suzuki, C.S. Sima, et al. Journal of Thoracic Oncology 2011;6(5):896-904. PubMed · Publisher
• Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. N.M. Rueth, S.E. Murray, S.J. Huddleston, et al. Annals of Surgical Oncology 2011;18(1):174-80. PubMed · Publisher
• Simple nutritional intervention in patients with advanced cancers of the gastrointestinal tract, non-small cell lung cancers or mesothelioma and weight loss receiving chemotherapy: a randomised controlled trial. C. Baldwin, A. Spiro, C. McGough, et al. Journal of Human Nutrition and Dietetics 2011;24(5):431-40. Randomized trial PubMed · Publisher
• Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. S. Bölükbas, C. Manegold, M. Eberlein, et al. Lung Cancer 2011;71(1):75-81. PubMed · Publisher
• Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. G. Lainakis, F. Zagouri, E. Kastritis, et al. Tumori 2011;97(1):25-9. PubMed · Publisher
• Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study. P. Schwarzenberger, P. Byrne, R. Gaumer, et al. Cancer Gene Therapy 2011;18(12):906-12. PubMed · Publisher
• Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. A. Scherpereel, T. Berghmans, J.J. Lafitte, et al. The European Respiratory Journal 2011;37(1):129-35. PubMed · Publisher
• A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. D.H. Sterman, A. Recio, A.R. Haas, et al. Molecular Therapy 2010;18(4):852-60. PubMed · Publisher · Free full text
• A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. S. Dubey, P.A. Jänne, L. Krug, et al. Journal of Thoracic Oncology 2010;5(10):1655-61. PubMed · Publisher · Free full text
• Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia. A. Hasani, K. Feeney, A. Nowak, et al. Asia-Pacific Journal of Clinical Oncology 2010;6(4):350-6. PubMed · Publisher
• Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. N. Katirtzoglou, I. Gkiozos, N. Makrilia, et al. Clinical Lung Cancer 2010;11(1):30-5. PubMed · Publisher
• Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. A. Cristaudo, R. Foddis, A. Bonotti, et al. The International Journal of Biological Markers 2010;25(3):164-70. PubMed · Publisher
• Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma. G. Marulli, F. Rea, S. Nicotra, et al. European Journal of Cardio-thoracic Surgery 2010;37(6):1464-9. PubMed · Publisher
• Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. R. Hassan, C. Schweizer, K.F. Lu, et al. Lung Cancer 2010;68(3):455-9. PubMed · Publisher · Free full text
• Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. M. Metintas, G. Ak, E. Dundar, et al. Chest 2010;137(6):1362-8. Randomized trial PubMed · Publisher
• Perineal mesh rectopexy with sterile talc in children with rectal prolapse. M. Nazem, M. Hosseinpour, M. Farhadi. European Journal of Pediatric Surgery 2010;20(5):321-4. Randomized trial PubMed · Publisher
• Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. R. Hassan, S.J. Cohen, M. Phillips, et al. Clinical Cancer Research 2010;16(24):6132-8. PubMed · Publisher · Free full text
• The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. B.S. Choi, D.B. Alberti, W.R. Schelman, et al. Cancer Chemotherapy and Pharmacology 2010;66(5):973-80. PubMed · Publisher · Free full text
• Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. P.E. Van Schil, P. Baas, R. Gaafar, et al. The European Respiratory Journal 2010;36(6):1362-9. PubMed · Publisher
• Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials. M.D. Kluger, R.N. Taub, M. Hesdorffer, et al. European Journal of Surgical Oncology 2010;36(10):997-1003. PubMed · Publisher
• WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. L.M. Krug, T. Dao, A.B. Brown, et al. Cancer Immunology, Immunotherapy 2010;59(10):1467-79. PubMed · Publisher · Free full text

2000s

• A possible association between aprotinin and improved survival after radical surgery for mesothelioma. P.H. Norman, P.F. Thall, R.V. Purugganan, et al. Cancer 2009;115(4):833-41. Randomized trial PubMed · Publisher · Free full text

• Comparison of diagnostic quality and accuracy in color-coded versus gray-scale DCE-MR imaging display. A. Mehndiratta, M.V. Knopp, C.M. Zechmann, et al. International Journal of Computer Assisted Radiology and Surgery 2009;4(5):457-62. PubMed · Publisher · Free full text

• Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. R.J. Kreitman, R. Hassan, D.J. Fitzgerald, et al. Clinical Cancer Research 2009;15(16):5274-9. PubMed · Publisher · Free full text

• Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. S.S. Ramalingam, C.P. Belani, C. Ruel, et al. Journal of Thoracic Oncology 2009;4(1):97-101. PubMed · Publisher · Free full text

• Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. M.F. Muers, R.J. Stephens, P. Fisher, et al. Lancet 2008;371(9625):1685-94. Randomized trial PubMed · Publisher · Free full text

• Fruit, vegetable, vitamin A intakes, and prostate cancer risk. G.L. Ambrosini, N.H. de Klerk, L. Fritschi, et al. Prostate Cancer and Prostatic Diseases 2008;11(1):61-6. Randomized trial PubMed · Publisher

• Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. G. Hillerdal, J.B. Sorensen, S. Sundström, et al. Journal of Thoracic Oncology 2008;3(11):1325-31. PubMed · Publisher

• A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. T.D. Yan, L. Welch, D. Black, et al. Annals of Oncology 2007;18(5):827-34. Systematic review PubMed · Publisher

  In plain English

  This article was a systematic review, not a new study of patients. The authors searched six medical databases, up to May 2006, for studies of diffuse malignant peritoneal mesothelioma, a cancer of the abdominal lining. Studies had to use cytoreductive surgery (removal of visible tumor) combined with chemotherapy placed directly into the abdomen around the time of surgery. They included seven reports from six specialist centers, covering 240 patients. All seven were observational studies without a comparison group, and no randomized trials were found. Across the studies, median survival ranged from 34 to 92 months, and it was not reached in two studies. Survival ranged from 60% to 88% at 1 year, 43% to 65% at 3 years, and 29% to 59% at 5 years. Complication rates around the time of surgery ranged from 25% to 40%, and death rates around the time of surgery from 0% to 8%. The authors concluded that the studies showed better overall survival than historical patients treated with systemic chemotherapy and palliative surgery. They noted possible selection bias, small studies, short follow-up in some, and differing treatment plans. The review did not study asbestos exposure.

  We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

• MESOMARK: a potential test for malignant pleural mesothelioma. H.L. Beyer, R.D. Geschwindt, C.L. Glover, et al. Clinical Chemistry 2007;53(4):666-72. PubMed · Publisher

• Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers. J.Y. Choi, M.L. Neuhouser, M. Barnett, et al. Cancer Epidemiology, Biomarkers & Prevention 2007;16(6):1115-20. Randomized trial PubMed · Publisher

• Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. R.M. Flores, M. Zakowski, E. Venkatraman, et al. Journal of Thoracic Oncology 2007;2(10):957-65. PubMed · Publisher

• Spirometry, rapid FEV1 decline, and lung cancer among asbestos exposed heavy smokers. J.W. Chien, D.H. Au, M.J. Barnett, et al. COPD 2007;4(4):339-46. Randomized trial PubMed · Publisher

• Management of malignant mesothelioma by decortication and adjunct phototherapy. C.P. Clarke, S.R. Knight, F.J. Daniel, et al. Asian Cardiovascular & Thoracic Annals 2006;14(3):206-9. PubMed · Publisher

• Nested case-control study of autoimmune disease in an asbestos-exposed population. C.W. Noonan, J.C. Pfau, T.C. Larson, et al. Environmental Health Perspectives 2006;114(8):1243-7. Randomized trial PubMed · Publisher · Free full text

• Changes in cholesterol and triglyceride concentrations in the Vanguard population of the Carotene and Retinol Efficacy Trial (CARET). B. Cartmel, J. Dziura, M.R. Cullen, et al. European Journal of Clinical Nutrition 2005;59(10):1173-80. Randomized trial PubMed · Publisher

• Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma. L. Portalone, A. Antilli, F. Nunziati, et al. Tumori 2005;91(1):15-8. PubMed · Publisher

• Predictors of lung cancer among asbestos-exposed men in the {beta}-carotene and retinol efficacy trial. M.R. Cullen, M.J. Barnett, J.R. Balmes, et al. American Journal of Epidemiology 2005;161(3):260-70. Randomized trial PubMed · Publisher

• Risk of lung cancer and leukemia from exposure to ionizing radiation and potential confounders among workers at the Portsmouth Naval Shipyard. J.H. Yiin, M.K. Schubauer-Berigan, S.R. Silver, et al. Radiation Research 2005;163(6):603-13. PubMed · Publisher

• The usefulness of computed tomography in detecting asbestos-related pleural abnormalities in people who had indeterminate chest radiographs: the Libby, MT, experience. O.I. Muravov, W.E. Kaye, M. Lewin, et al. International Journal of Hygiene and Environmental Health 2005;208(1-2):87-99. PubMed · Publisher

• A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. S. Bydder, M. Phillips, D.J. Joseph, et al. British Journal of Cancer 2004;91(1):9-10. Randomized trial PubMed · Publisher · Free full text

• The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. G.E. Goodman, M.D. Thornquist, J. Balmes, et al. Journal of the National Cancer Institute 2004;96(23):1743-50. Randomized trial PubMed · Publisher

• A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473). P. Beale, I. Judson, A. O'Donnell, et al. British Journal of Cancer 2003;88(7):1128-34. PubMed · Publisher · Free full text

• A pilot study of telephone-based smoking cessation intervention in asbestos workers. O.Y. Osinubi, J. Moline, E. Rovner, et al. Journal of Occupational and Environmental Medicine 2003;45(5):569-74. Randomized trial PubMed · Publisher

• Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. D.T. Le, M. Deavers, K. Hunt, et al. Cancer Investigation 2003;21(5):682-9. PubMed · Publisher

• Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies. O. Monneuse, A.C. Beaujard, B. Guibert, et al. British Journal of Cancer 2003;88(12):1839-43. PubMed · Publisher · Free full text

• A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. A.K. Nowak, M.J. Byrne, R. Williamson, et al. British Journal of Cancer 2002;87(5):491-6. PubMed · Publisher · Free full text

• Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. R. Mendes, M.E. O'Brien, A. Mitra, et al. British Journal of Cancer 2002;86(3):336-41. PubMed · Publisher · Free full text

• Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?. C. Porta, V. Rizzo, M. Zimatore, et al. Lung Cancer 2002;38(2):159-62. PubMed · Publisher

• Malignant pleural mesothelioma: a phase II trial with docetaxel. D.A. Vorobiof, B.L. Rapoport, M.R. Chasen, et al. Annals of Oncology 2002;13(3):412-5. PubMed · Publisher

• Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council. D.J. Girling, M.F. Muers, W. Qian, et al. Seminars in Oncology 2002;29(1):97-101. Randomized trial · Review PubMed · Publisher

• Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. J.M. van Haarst, P. Baas, C.H. Manegold, et al. British Journal of Cancer 2002;86(3):342-5. PubMed · Publisher · Free full text

• Occupational airborne exposure and the incidence of respiratory symptoms and asthma. T.M. Eagan, A. Gulsvik, G.E. Eide, et al. American Journal of Respiratory and Critical Care Medicine 2002;166(7):933-8. Randomized trial PubMed · Publisher

• Phase II trial of ZD0473 as second-line therapy in mesothelioma. G. Giaccone, M.E. O'Brien, M.J. Byrne, et al. European Journal of Cancer 2002;38 Suppl 8:S19-24. PubMed · Publisher

• Smoking enhances asbestos-induced genotoxicity, relative involvement of chromosome 1: a study using multicolor FISH with tandem labeling. M. Lohani, E. Dopp, H.H. Becker, et al. Toxicology Letters 2002;136(1):55-63. PubMed · Publisher

• A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. C. Huisman, P.E. Postmus, G. Giaccone, et al. Annals of Oncology 2001;12(11):1567-73. PubMed · Publisher

• A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. C.W. Mulatero, R.T. Penson, D. Papamichael, et al. Lung Cancer 2001;31(1):67-72. PubMed · Publisher

• Agreement between a brief food frequency questionnaire and diet records using two statistical methods. G.L. Ambrosini, N.H. de Klerk, A.W. Musk, et al. Public Health Nutrition 2001;4(2):255-64. Randomized trial PubMed · Publisher

• Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. C. Pinto, A. Marino, M. Guaraldi, et al. American Journal of Clinical Oncology 2001;24(2):143-7. PubMed · Publisher

• Educational differences in lung cancer mortality in male smokers. P. Martikainen, E. Lahelma, S. Ripatti, et al. International Journal of Epidemiology 2001;30(2):264-7. Randomized trial PubMed · Publisher

• High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. M.P. Kosty, J.E. Herndon, N.J. Vogelzang, et al. Lung Cancer 2001;34(2):289-95. PubMed · Publisher

• Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study. R. Maisano, N. Caristi, G. Toscano, et al. Tumori 2001;87(6):391-3. PubMed · Publisher

• Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. B. Castagneto, S. Zai, L. Mutti, et al. Lung Cancer 2001;31(2-3):303-10. PubMed · Publisher

• Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. J.P. Steele, C.A. O'Doherty, J. Shamash, et al. Annals of Oncology 2001;12(4):497-9. PubMed · Publisher

• 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study. A. Carretta, C. Landoni, G. Melloni, et al. European Journal of Cardio-thoracic Surgery 2000;17(4):377-83. PubMed · Publisher

• A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. J.P. Delord, E. Raymond, M. Chaouche, et al. Annals of Oncology 2000;11(1):73-9. PubMed · Publisher

• A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. D.H. Sterman, K. Molnar-Kimber, T. Iyengar, et al. Cancer Gene Therapy 2000;7(12):1511-8. PubMed · Publisher

• A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. M.E. O'Brien, A. Saini, I.E. Smith, et al. British Journal of Cancer 2000;83(7):853-7. Randomized trial PubMed · Publisher · Free full text

• Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study. A. Knuuttila, T. Ollikainen, M. Halme, et al. Anti-cancer Drugs 2000;11(4):257-61. PubMed · Publisher

• Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. L.H. Harrison, P.O. Schwarzenberger, P.S. Byrne, et al. The Annals of Thoracic Surgery 2000;70(2):407-11. PubMed · Publisher

• High-resolution computed tomography in cases with environmental exposure to asbestos in Turkey. F. Topçu, H. Bayram, M. Simşek, et al. Respiration; International Review of Thoracic Diseases 2000;67(2):139-45. Comment PubMed · Publisher

• Malignant mesothelioma: predictors of prognosis and clinical trials. J.P. Steele, R.M. Rudd. Thorax 2000;55(9):725-6. Comment · Editorial PubMed · Publisher · Free full text

• Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours. S.L. Cheeseman, M. Brannan, A. McGown, et al. British Journal of Cancer 2000;83(12):1599-606. PubMed · Publisher · Free full text

• Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. A.A. Adjei, C. Erlichman, J.A. Sloan, et al. Journal of Clinical Oncology 2000;18(8):1748-57. PubMed · Publisher

• Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. K. Fizazi, M. Ducreux, P. Ruffié, et al. Journal of Clinical Oncology 2000;18(11):2293-300. PubMed · Publisher

• Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. S.C. White, H. Anderson, G.C. Jayson, et al. Annals of Oncology 2000;11(2):201-6. Randomized trial PubMed · Publisher

• Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. S. Mukherjee, T. Haenel, R. Himbeck, et al. Cancer Gene Therapy 2000;7(5):663-70. PubMed · Publisher

1990s

• Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. R. Thödtmann, H. Depenbrock, H. Dumez, et al. Journal of Clinical Oncology 1999;17(10):3009-16. PubMed · Publisher
• Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis. A.M. Björkqvist, M. Wolf, S. Nordling, et al. British Journal of Cancer 1999;81(7):1111-5. PubMed · Publisher · Free full text
• High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. M. Halme, A. Knuuttila, T. Vehmas, et al. British Journal of Cancer 1999;80(11):1781-5. PubMed · Publisher · Free full text
• Ifosfamide in malignant mesothelioma: a phase II study. M.K. Andersen, A. Krarup-Hansen, G. Mårtensson, et al. Lung Cancer 1999;24(1):39-43. PubMed · Publisher
• Predictors of participant retention in two chemoprevention feasibility trials. D.J. Bowen, B. Cartmel, M. Barnett, et al. Annals of Behavioral Medicine 1999;21(3):210-5. Randomized trial PubMed · Publisher
• Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). B.J. Park, H.R. Alexander, S.K. Libutti, et al. Annals of Surgical Oncology 1999;6(6):582-90. PubMed · Publisher
• Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. S. Bretti, A. Berruti, L. Dogliotti, et al. Tumori 1998;84(5):558-61. PubMed · Publisher
• Effectiveness of postal smoking cessation advice: a randomized controlled trial in young men with reduced FEV1 and asbestos exposure. S. Humerfelt, G.E. Eide, G. Kvåle, et al. The European Respiratory Journal 1998;11(2):284-90. Randomized trial PubMed · Publisher
• Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. J.E. Herndon, M.R. Green, A.P. Chahinian, et al. Chest 1998;113(3):723-31. PubMed · Publisher
• Mailing strategies and costs of recruiting heavy smokers in CARET, a large chemoprevention trial. B. Valanis, J. Blank, A. Glass. Controlled Clinical Trials 1998;19(1):25-38. Randomized trial PubMed · Publisher
• Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. C. Sessa, C. Minoia, A. Ronchi, et al. Annals of Oncology 1998;9(12):1315-22. PubMed · Publisher
• Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. I. Rassmann, R. Thödtmann, M. Mross, et al. Investigational New Drugs 1998;16(4):319-24. PubMed · Publisher
• Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. L.L. Herscher, S.M. Hahn, G. Kroog, et al. Journal of Clinical Oncology 1998;16(2):635-41. PubMed · Publisher
• Vitamin A and cancer prevention I: observations in workers previously exposed to asbestos at Wittenoom, Western Australia. A.W. Musk, N.H. de Klerk, G.L. Ambrosini, et al. International Journal of Cancer 1998;75(3):355-61. PubMed · Publisher
• Vitamin A and cancer prevention II: comparison of the effects of retinol and beta-carotene. N.H. de Klerk, A.W. Musk, G.L. Ambrosini, et al. International Journal of Cancer 1998;75(3):362-7. Randomized trial PubMed · Publisher
• Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma. A. Purohit, L. Moreau, A. Dietemann, et al. Lung Cancer 1998;22(2):119-25. PubMed · Publisher
• Analysis of asbestos fiber burden in lung tissue from mesothelioma patients. R.F. Dodson, M. O'Sullivan, C.J. Corn, et al. Ultrastructural Pathology 1997;21(4):321-36. PubMed · Publisher
• Memory deficits and industrial toxicant exposure: a comparative study of hard metal, solvent and asbestos workers. C.M. Jordan, R.D. Whitman, M. Harbut. The International Journal of Neuroscience 1997;90(1-2):113-28. PubMed · Publisher
• Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. C.A. Johnson, D. Kilpatrick, R. von Roemeling, et al. Journal of Clinical Oncology 1997;15(2):773-80. PubMed · Publisher
• Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. H.I. Pass, B.K. Temeck, K. Kranda, et al. Annals of Surgical Oncology 1997;4(8):628-33. Randomized trial PubMed · Publisher
• Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. P. Baas, L. Murrer, F.A. Zoetmulder, et al. British Journal of Cancer 1997;76(6):819-26. PubMed · Publisher · Free full text
• Simultaneous occurrence of a rectal carcinoma and a diffuse well differentiated papillary mesothelioma of the peritoneum. G.R. Jatzko, J. Jester. International Journal of Colorectal Disease 1997;12(6):326-8. Case report PubMed · Publisher
• Strategy for the treatment of patients with spinal neoplasms. P. Kluger, A. Korge, H.P. Scharf. Spinal Cord 1997;35(7):429-36. Case report PubMed · Publisher
• The CARET asbestos-exposed cohort: baseline characteristics and comparison to other asbestos-exposed cohorts. S. Barnhart, J. Keogh, M.R. Cullen, et al. American Journal of Industrial Medicine 1997;32(6):573-81. PubMed · Publisher
• Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. M.Y. Chen, C. Chiles, B.W. Loggie, et al. Journal of Surgical Oncology 1997;66(1):19-23. PubMed · Publisher
• Beta carotene fails to prevent cancer in two major studies; CARET intervention stopped. K. Smigel. Journal of the National Cancer Institute 1996;88(3-4):145. News PubMed · Publisher
• Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. P. Soulié, P. Ruffié, L. Trandafir, et al. Journal of Clinical Oncology 1996;14(3):878-85. PubMed · Publisher
• Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. G.S. Omenn, G.E. Goodman, M.D. Thornquist, et al. The New England Journal of Medicine 1996;334(18):1150-5. Randomized trial PubMed · Publisher
• Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies. H.B. Ris, H.J. Altermatt, B. Nachbur, et al. Lasers in Surgery and Medicine 1996;18(1):39-45. PubMed · Publisher
• Longitudinal pattern of reported respiratory symptoms and accelerated ventilatory loss in asbestos-exposed workers. C.A. Brodkin, S. Barnhart, H. Checkoway, et al. Chest 1996;109(1):120-6. Randomized trial PubMed · Publisher
• Lung cinescintigraphy in the dynamic assessment of ventilation and mucociliary clearance of asbestos cement workers. L. Di Lorenzo, M. Mele, M.M. Pegorari, et al. Occupational and Environmental Medicine 1996;53(9):628-35. PubMed · Publisher · Free full text
• Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. J. van Meerbeeck, C. Debruyne, N. van Zandwijk, et al. British Journal of Cancer 1996;74(6):961-3. PubMed · Publisher · Free full text
• Relevance of asbestos bodies in sputum. H. Teschler, A.B. Thompson, R. Dollenkamp, et al. The European Respiratory Journal 1996;9(4):680-6. PubMed · Publisher
• Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. G.S. Omenn, G.E. Goodman, M.D. Thornquist, et al. Journal of the National Cancer Institute 1996;88(21):1550-9. Randomized trial PubMed · Publisher
• Two dose levels of ifosfamide in malignant mesothelioma. F. Içli, H. Karaoğuz, S. Hastürk, et al. Lung Cancer 1996;15(2):207-13. PubMed · Publisher
• Beta-Carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. J.W. McLarty, D.B. Holiday, W.M. Girard, et al. The American Journal of Clinical Nutrition 1995;62(6 Suppl):1431S-1438S. Randomized trial PubMed · Publisher
• Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. S.H. Goey, A.M. Eggermont, C.J. Punt, et al. British Journal of Cancer 1995;72(5):1283-8. PubMed · Publisher · Free full text
• Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. E.R. Sauter, C. Langer, L.R. Coia, et al. Journal of Surgical Oncology 1995;60(2):100-5. PubMed · Publisher
• Potential pitfall in using cumulative exposure in exposure-response relationships: demonstration and discussion. M.M. Finkelstein. American Journal of Industrial Medicine 1995;28(1):41-7. Randomized trial PubMed · Publisher
• A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. L.Y. Dirix, J. van Meerbeeck, D. Schrijvers, et al. Annals of Oncology 1994;5(7):653-5. PubMed · Publisher
• A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. V. Rusch, L. Saltz, E. Venkatraman, et al. Journal of Clinical Oncology 1994;12(6):1156-63. PubMed · Publisher
• Mesothelioma among car mechanics?. H.J. Woitowitz, K. Rödelsperger. The Annals of Occupational Hygiene 1994;38(4):635-8. PubMed · Publisher
• Oral etoposide in the treatment of malignant mesothelioma. A phase II study. L. Tammilehto, P. Maasilta, M. Mäntylä, et al. Annals of Oncology 1994;5(10):949-50. PubMed · Publisher
• Phase I study of the novel distamycin derivative tallimustine (FCE 24517). C. Sessa, O. Pagani, M.G. Zurlo, et al. Annals of Oncology 1994;5(10):901-7. PubMed · Publisher
• Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. A.M. Oza, W. ten Bokkel Huinink, R. Dubbelman, et al. Annals of Oncology 1994;5(4):343-7. PubMed · Publisher
• The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. G.S. Omenn, G. Goodman, M. Thornquist, et al. Cancer Research 1994;54(7 Suppl):2038s-2043s. Randomized trial PubMed
• Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. S. Tansan, S. Emri, T. Selçuk, et al. Oncology 1994;51(4):348-51. PubMed · Publisher
• Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. N.J. Vogelzang, L.B. Weissman, J.E. Herndon, et al. Journal of Clinical Oncology 1994;12(7):1436-42. PubMed · Publisher
• Weekly high-dose cisplatin in malignant pleural mesothelioma. A.S. Planting, J.H. Schellens, S.H. Goey, et al. Annals of Oncology 1994;5(4):373-4. PubMed · Publisher
• A phase I study of intravenous bryostatin 1 in patients with advanced cancer. J. Prendiville, D. Crowther, N. Thatcher, et al. British Journal of Cancer 1993;68(2):418-24. PubMed · Publisher · Free full text
• Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. P. Astoul, J.R. Viallat, J.C. Laurent, et al. Chest 1993;103(1):209-13. PubMed · Publisher
• Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. A.S. Planting, M.E. van der Burg, M. de Boer-Dennert, et al. British Journal of Cancer 1993;68(4):789-92. PubMed · Publisher · Free full text
• Research cost analyses to aid in decision making in the conduct of a large prevention trial, CARET. Carotene and Retinol Efficacy Trial. M.D. Thornquist, N. Urban, A. Tseng, et al. Controlled Clinical Trials 1993;14(4):325-39. Randomized trial PubMed · Publisher
• Statistical design and monitoring of the Carotene and Retinol Efficacy Trial (CARET). M.D. Thornquist, G.S. Omenn, G.E. Goodman, et al. Controlled Clinical Trials 1993;14(4):308-24. Randomized trial PubMed · Publisher
• Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. K. Mattson, G. Giaccone, A. Kirkpatrick, et al. Journal of Clinical Oncology 1992;10(5):824-8. PubMed · Publisher
• High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. O.P. Solheim, G. Saeter, A.M. Finnanger, et al. British Journal of Cancer 1992;65(6):956-60. PubMed · Publisher · Free full text
• Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. M.D. Magri, S. Foladore, A. Veronesi, et al. Annals of Oncology 1992;3(3):237-8. PubMed · Publisher
• A historical prospective study of European stainless steel, mild steel, and shipyard welders. L. Simonato, A.C. Fletcher, A. Andersen, et al. British Journal of Industrial Medicine 1991;48(3):145-54. PubMed · Publisher · Free full text
• CARET, the beta-carotene and retinol efficacy trial to prevent lung cancer in asbestos-exposed workers and in smokers. G.S. Omenn, G. Goodman, J. Grizzle, et al. Anti-cancer Drugs 1991;2(1):79-86. Randomized trial PubMed · Publisher
• Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. V.W. Rusch, R. Figlin, D. Godwin, et al. Journal of Clinical Oncology 1991;9(2):313-9. PubMed · Publisher
• Participation and adherence among older men and women recruited to the Beta-Carotene and Retinol Efficacy trial (CARET). M.D. Thornquist, D.L. Patrick, G.S. Omenn. The Gerontologist 1991;31(5):593-7. PubMed · Publisher
• Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. R.J. Parker, I. Gill, R. Tarone, et al. Carcinogenesis 1991;12(7):1253-8. PubMed · Publisher
• Comparison of chest radiograph reading methods for assessing progress of pneumoconiosis over 10 years in Wittenoom crocidolite workers. N.H. de Klerk, A.W. Musk, A. James, et al. British Journal of Industrial Medicine 1990;47(2):127-31. Randomized trial PubMed · Publisher · Free full text
• Different imaging methods in the assessment of radiation-induced lung injury following hemithorax irradiation for pleural mesothelioma. P. Maasilta, L. Kivisaari, K. Mattson. Radiotherapy and Oncology 1990;19(2):159-67. PubMed · Publisher

1980s

• Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. P. Ruffie, R. Feld, S. Minkin, et al. Journal of Clinical Oncology 1989;7(8):1157-68. PubMed · Publisher
• Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985. A. Calavrezos, G. Koschel, H. Hüsselmann, et al. Klinische Wochenschrift 1988;66(14):607-13. PubMed · Publisher
• Surgical treatment of asbestos-related disease of the chest. L.P. Faber. The Surgical Clinics of North America 1988;68(3):525-43. PubMed · Publisher
• Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. M.K. Samson, L.P. Wasser, E.C. Borden, et al. Journal of Clinical Oncology 1987;5(1):86-91. Randomized trial PubMed · Publisher
• An ultrastructural comparison of mesotheliomas with adenocarcinomas of the lung and breast. M.J. Warhol, J.M. Corson. Human Pathology 1985;16(1):50-5. PubMed · Publisher
• Use of job-exposure matrix in an occupational analysis of lung and bladder cancers on the basis of death certificates. D. Coggon, B. Pannett, E.D. Acheson. Journal of the National Cancer Institute 1984;72(1):61-5. PubMed · Publisher
• Chemotherapy for malignant mesothelioma; CAMEO. J.R. Jett, R.T. Eagan. American Journal of Clinical Oncology 1982;5(4):429-31. PubMed · Publisher

1970s

• Report of the Advisory Committee on Asbestos Cancers to the Director of the International Agency for Research on Cancer. British Journal of Industrial Medicine 1973;30(2):180-6. PubMed · Free full text
• Induction of interferon in human subjects by poly I:C. A.K. Field, C.W. Young, I.H. Krakoff, et al. Proceedings of the Society for Experimental Biology and Medicine 1971;136(4):1180-6. PubMed · Publisher

Browse every journal in the library or other types of article.